Sharps Tech Stock Price, News & Analysis

Sharps Technology (NASDAQ: STSS, STSSW) has secured a $30 million purchase order from Nephron Pharmaceuticals for their first 12 months of prefillable copolymer syringes. The syringes, available in 10mL and 50mL sizes, will be manufactured at a newly acquired facility in West Columbia, South Carolina. This purchase order is part of a larger five-year, $200 million Syringe Sales Agreement. The new facility, expected to be operational by Q2 2025, aims to exceed $35 million in revenue in its first year, with projections of over $50 million in 2026, and potentially $100 million by 2028. The advanced syringe technology offers significant benefits, including reduced breakage and contamination, and improved cold-chain storage.

Soligenix and Sharps Technology will be featured in interviews on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, airing June 8 at 7 p.m. ET. Soligenix, a late-stage biopharmaceutical company, highlights its promising portfolio, including HyBryte™ for cutaneous T-cell lymphoma, which showed positive Phase 3 results and has a $250 million market potential. It also features SGX302 for psoriasis and SGX203 for pediatric Crohn's disease, targeting markets over $1 billion collectively. Sharps Technology, meanwhile, has secured a $200 million Sales Agreement and acquired Nephron Pharmaceuticals' InjectEZ facility, positioning itself as North America's first dedicated polymer prefillable syringe manufacturer. Projected revenues include $35 million in the first 12 months, with potential growth up to $100 million by 2028.

Sharps Technology has secured exclusive rights to purchase InjectEZ assets with a $1 million escrow deposit. The acquisition includes a five-year, $200 million syringe sales agreement with Nephron Pharmaceuticals. The transaction is expected to close within 60 days, with product shipments slated to begin in Q2 2025. The South Carolina facility will produce pharmaceutical-grade prefillable syringes, with projected revenue exceeding $35 million in the first 12 months. The manufacturing plan includes three phases, with the final phase expected to be completed by October 2027. Sharps is also collaborating with Fortune 500 medical distributors and pharmaceutical companies to expand its market reach.

Sharps Technology (NASDAQ: STSS) has signed an enhanced Asset Purchase Agreement with Nephron Pharmaceuticals to acquire InjectEZ manufacturing assets in South Carolina. The $35 million acquisition includes a five-year, $200 million syringe Sales Agreement, positioning Sharps as the first dedicated polymer prefillable syringe manufacturer in North America. Expected revenues are $35 million in the first 12 months, with potential growth to $100 million by 2028. The facility will start delivering products by Q2 2025. The deal also involves a $9 million and $4.75 million investment for production line expansions, potentially adding $65 million in annual revenue by 2027. This strategic move is fueled by FDA recalls, tariffs, and a shift from glass to polymer syringes.

Sharps Technology has signed a $200 million, 5-year syringe sales agreement with Nephron Pharmaceuticals and an asset purchase agreement (APA) to acquire InjectEZ's syringe manufacturing assets for $35 million. This acquisition, expected to close within 60 days, will establish a dedicated prefillable syringe manufacturing plant in West Columbia, SC. The facility aims to start production by Q2 2025, projecting $37 million in revenue in the first 12 months. This deal expands Sharps' manufacturing capacity in the U.S. and Europe and positions the company for growth in the copolymer prefillable syringe market.

Sharps Technology (NASDAQ: STSS) CEO Robert Hayes addresses shareholders about the impact of recent FDA actions and tariffs. The FDA raised quality concerns over Chinese syringes in November 2023, leading to recalls and warnings in early 2024. The Biden Administration increased tariffs on Chinese syringes from 0% to 50% in May 2024. Sharps Technology, with its high-quality syringe products like SecureGard and SoloGard, is poised to fill the supply gap. The company manufactures in Hungary and plans to add a US facility. Sharps has also formed partnerships with Roncadelle Operations and Owens & Minor to expand market reach and distribution. These steps are expected to drive revenue growth and market presence.